Diabetes medicine linked to decrease threat of dementia

These medicine can efficiently stop dementia in high-risk folks with delicate or reasonable sort 2 diabetes.

In response to the scientists, it might be helpful to prioritize these medicine for future replication analysis.

In response to a long-term examine just lately revealed within the Open Entry Journal BMJ Open Diabetes Analysis and Care, use of a diabetes drug often called glutazone was related to a 22% decrease threat of dementia. Glitazones, usually abbreviated as thiazolidinediones or TZDs, are an older class of sort 2 diabetes medicines.

In response to the researchers, these medicine can successfully stop dementia in high-risk folks with mild-to-moderate sort 2 diabetes, and it might be value contemplating them in future medical trials to find out if that is so. Prioritize whether or not they are often reused.

Researchers have begun investigating whether or not diabetes medicine may doubtlessly assist stop or treatment dementia as a result of sort 2 diabetes and dementia share many physiological patterns. Nevertheless, outcomes have been inconsistent up to now.

To shed extra gentle on this, researchers in contrast the incidence of dementia in older adults with sort 2 diabetes who have been receiving both a sulfonylurea or a thiazolidinedione (TZD).

They used knowledge from 559,106 folks with sort 2 diabetes who have been identified within the nationwide Veterans Affairs (VA) well being system between January 2000 and December 2019.

Solely aged sufferers (a minimum of 60 years of age) and a primary prescription of metformin, a sulfonylurea (tolbutamide, glimepiride, glipizide, or glyburide) or a TZD (rosiglitazone or pioglitazone) between January 2001 and December 2017 have been included. (559,106) examine. Their well being was monitored for a median of 8 years.

After a minimum of 1 yr of drug remedy, TZD use alone was related to a 22% decrease threat of dementia from any trigger, in contrast with metformin use alone.

Particularly, it was related to an 11 p.c decrease threat.[{” attribute=””>Alzheimer’s disease and a 57% lower risk of vascular dementia. Given that vascular diseases increase the risk of Alzheimer’s disease, TZDs may also help to reduce dementia and Alzheimer’s disease in part through their favorable effects on the vascular system, say the researchers.

While the risk of dementia from any cause was 11% lower for the use of metformin and TZD combined, it was 12% higher for the use of a sulfonylurea drug alone, prompting the researchers to suggest that supplementing a sulfonylurea with either metformin or a TZD may partially offset these effects.

Further in-depth analysis indicated that those younger than 75 benefited more from a TZD than older patients, highlighting the importance of early prevention for dementia, note the researchers. And these drugs also seemed to be more protective in overweight or obese patients.

This is an observational study, so definitive conclusions can’t be drawn about cause and effect. And the researchers acknowledge that certain potentially influential information wasn’t available, including kidney function and genetic factors, and that study participants were predominantly male and White.

But they suggest that future studies for repurposing diabetes drugs for dementia prevention might want to consider prioritizing TZDs, based on their findings.

And they conclude: “These findings may help inform medication selection for [older] Sufferers with [type 2 diabetes] at larger threat of dementia.”

Quotation: “Use of Oral Diabetes Drugs and Danger of Dementia in US Veterans ≥60 Years of Age with Kind 2 Diabetes” by Xin Tang, Roberta Diaz Brinton, Zhao Chen, Leslie V. Farland, Yann Klimentidis, Raymond Migrino , Peter Reaven to Kathleen Rogers and Jin Jay Zhou, 11 Oct. 2022, BMJ Open Diabetes Analysis and Care.
DOI: 10.1136/bmjdrc-2022-002894

The examine was funded by the Nationwide Human Genome Analysis Institute, the Nationwide Science Basis, the Nationwide Institute of Diabetes and Digestive and Kidney Ailments, and the Nationwide Coronary heart, Lung, and Blood Institute.

About the author


Leave a Comment